Defunct Company
Total Trials
10
As Lead Sponsor
As Collaborator
0
Total Enrollment
3,424
NCT02310802
OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 30, 2014
Completion: Dec 31, 2016
NCT02326142
A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth
Start: Mar 31, 2015
Completion: Oct 31, 2017
NCT02778399
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
Start: Jul 31, 2016
Completion: Jul 1, 2019
NCT03081208
Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI
Phase: Phase 3
Start: Mar 6, 2017
Completion: Feb 19, 2019
NCT03070899
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Start: Apr 20, 2017
Completion: Apr 12, 2021
NCT03070951
Start: May 23, 2017
Completion: Oct 4, 2020
NCT03369262
PoC Study of OBE022 in Threatened Preterm Labour
Start: Jan 10, 2018
Completion: Aug 31, 2022
NCT03758885
Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF
Start: Jan 10, 2019
Completion: Nov 11, 2020
NCT03961932
Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
Phase: Phase 1
Start: May 15, 2019
Completion: Jan 31, 2020
NCT03962049
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
Completion: Nov 1, 2019